List view / Grid view


ORYZON appoints Greg Weaver as Global Chief Financial Officer

12 January 2015 | By Oryzon

Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015...

Protagen AG appoints Bernhard Kirschbaum as new Board Member

8 January 2015 | By PROTAGEN AG

PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board...

SciFluor Life Sciences awarded U.S. Patent for KCNQ2/3 activator designed for treatment of epilepsy and related neurological disorders

8 January 2015 | By SciFluor Life Sciences

SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...